(Q36003103)

11 August 2017

1 reference

title

The role of allogeneic transplantation in non-Hodgkin's lymphoma (English)

1 reference

11 August 2017

3

David C Linch

1 reference

11 August 2017

Karl S Peggs

1

1 reference

11 August 2017

Stephen Mackinnon

series ordinal

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

British Journal of Haematology

11 August 2017

published in

1 reference

11 August 2017

volume

128

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

153-168

1 reference

Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Allogeneic bone marrow transplantation for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Richter's syndrome after allogeneic stem cell transplantation for chronic lymphocytic leukaemia successfully treated by withdrawal of immunosuppression, and donor lymphocyte infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05251.X

10.1111/J.1365-2141.2004.05251.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference